Free tool
Drug Search
Every brand-name drug and biologic application (NDA or BLA) in Drugs@FDA: 5,899 in all. Generic (ANDA) applications are not listed; their reference drug is.
Last checked: Nov 20, 2026Drugs@FDA last updated: Nov 18, 2026Methods & limitations
7 matches for "Ipsen"
Brand names that start with your search come first, then marketed and novel drugs.
| Drug | Sponsor | Application | First approved | Programs |
|---|---|---|---|---|
| Dysport Abobotulinumtoxina | Ipsen Biopharm LTD | BLA125274 | Apr 29, 2009 | NovelOrphan |
| Increlex Mecasermin Recombinant | Ipsen INC | BLA021839 | Aug 30, 2005 | NovelPriority reviewOrphan |
| Iqirvo Elafibranor | Ipsen | NDA218860 | Jun 10, 2024 | NovelBreakthrough therapyAccelerated approvalPriority reviewOrphan |
| Bylvay Odevixibat | Ipsen | NDA215498 | Jul 20, 2021 | NovelPriority reviewOrphan |
| Sohonos Palovarotene | Ipsen | NDA215559 | Aug 16, 2023 | NovelPriority reviewOrphan |
| Somatuline Depot Lanreotide Acetate | Ipsen Pharma | NDA022074 | Aug 30, 2007 | NovelOrphan |
| Onivyde Irinotecan Hydrochloride | Ipsen | NDA207793 | Oct 22, 2015 | Priority reviewOrphan |
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.